A Large Outbreak of Fulminant Bacterial Endophthalmitis after Intravitreal Injection of Counterfeit Bevacizumab

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 254, Issue 9, 2016, Pages 1851-1856

  Entezari, Morteza ^a   Karimi, Saeed ^b   Ahmadieh, Hamid ^c   Mahmoudi, Amir Hossein ^d   Parhizgar, Hamid ^d   Yaseri, Mehdi ^e  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Shahid Beheshti University of Medical Sciences   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bevacizumab; Endophthalmitis; Outbreak

Indexed keywords

BEVACIZUMAB; CEFTAZIDIME; SILICONE OIL; STEROID; VANCOMYCIN; ANGIOGENESIS INHIBITOR;

ADULT; AGED; ARTICLE; BACTERIAL ENDOPHTHALMITIS; CITROBACTER; CLINICAL ARTICLE; CLINICAL FEATURE; ENDOPHTHALMITIS; EPIDEMIC; ESCHERICHIA COLI; EYE; FEMALE; HUMAN; KERATITIS; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; OUTCOME ASSESSMENT; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; VERY ELDERLY; VISUAL ACUITY; VITRECTOMY; ACUTE DISEASE; CLINICAL TRIAL; EYE INFECTIONS, BACTERIAL; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; IRAN; MULTICENTER STUDY; RETINAL DISEASES; RETROSPECTIVE STUDY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DISEASE OUTBREAKS; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; IRAN; MALE; MIDDLE AGED; RETINAL DISEASES; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 84976873283     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-016-3426-7     Document Type: Article

References (44)

1. Velez-Montoya R, Oliver SC, Olson JL, Fine SL, Mandava N, Quiroz-Mercado H (2013) Current knowledge and trends in age-related macular degeneration: today’s and future treatments. Retina 33:1487–1502
2. Bakri SJ, Larson TA, Edwards AO (2008) Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 246:779–781
3. Velez-Montoya R, Oliver SC, Olson JL, Fine SL, Quiroz-Mercado H, Mandava N (2014) Current knowledge and trends in age-related macular degeneration: genetics, epidemiology, and prevention. Retina 34:423–441
4. Kimoto K, Kubota T (2012) Anti-VEGF agents for ocular angiogenesis and vascular permeability. J Ophthalmol 2012:852183
5. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035–1047
6. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331–335
7. Ziemssen F, Sobolewska B (2011) Therapeutic efficacy of bevacizumab for age-related macular degeneration: what are the implications of CATT for routine management? Drugs Aging 28:853–865
8. Jansen RM (2013) The off-label use of medication: the latest on the Avastin – Lucentis debacle. Med Law 32:65–77
9. McCannel CA (2011) Meta-analysis of endophthalmitis following intravitreal injection of anti-VEGF agents: causative organisms and possible prevention strategies. Retina 31:654–661
10. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr et al (2011) Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 31:662–668
11. Yamashiro K, Tsujikawa A, Miyamoto K et al (2010) Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 30:485–490
12. The CATT Research Group (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908
13. Liu L, Ammar DA, Ross LA, Mandava N, Kahook MY, Carpenter JF (2011) Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 52:1023–1034
14. Fielden M, Nelson B, Kherani A (2011) Acute intraocular inflammation following intravitreal injection of bevacizumab – a large cluster of cases. Acta Ophthalmol 89:e664–e665
15. Good TJ, Kimura AE, Mandava N, Kahook MY (2011) Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 95:1111–1114
16. Yeh S, Albini TA, Moshfeghi AA, Nussenblatt RB (2012) Uveitis, the comparison of age-related macular degeneration treatments trials (CATT), and intravitreal biologics for ocular inflammation. Am J Ophthalmol 154:429–435
17. Damasceno N, Horowitz S, Damasceno E (2012) Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: uncommon complication. Clin Ophthalmol 6:1201–1205
18. Marticorena J, Romano V, Gómez-Ulla F (2012) Sterile endophthalmitis after intravitreal injections. Mediat Inflamm 2012:928123
19. Sheyman AT, Cohen BZ, Friedman AH, Ackert JM (2013) An outbreak of fungal endophthamitis after intravitreal injection of compounded combined bevacizumab and triamcinolone. JAMA Ophthalmol 131:864–869
20. Goldberg RA, Flynn HW Jr, Miller D, Gonzalez S, Isom RF (2013) Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: 1-year outcomes and investigative results. Ophthalmology 120:1448–1453
21. Yamashiro K, Tsujikawa A, Miyamoto K et al (2010) Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 30:485–490
22. Khan P, Khan L, Mondal P (2013) Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Indian J Ophthalmol
23. Entezari M, Ramezani A, Ahmadieh H, Ghasemi H (2014) Batch-related sterile endophthalmitis following intravitreal injection of bevacizumab. Indian J Ophthalmol 62:468–471
24. Wang F, Yu S, Liu K, Chen FE, Song Z, Zhang X, Xu X, Sun X (2013) Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China. Ophthalmology 120:355–360
25. Miller JM, Scott IU, Flynn HW Jr et al (2004) Endophthalmitis caused by Streptococcus pneumoniae. Am J Ophthalmol 138:231–236
26. Chan CC, Holland EJ, Sawyer WI, Neff KD, Petersen MR, Riemann CD (2011) Boston type 1 keratoprosthesis combined with silicone oil for treatment of hypotony in prephthisical eyes. Cornea 30:1105–1109
27. Alexandridis E (1990) Silicone oil tamponade in the management of severe hemorrhagic detachment of the choroid and ciliary body after surgical trauma. Ophthalmologica 200:189–193
28. Skorpik C, Menapace R, Gnad HD, Paroussis P (1989) Silicone oil implantation in penetrating injuries complicated by PVR. Results from 1982 to 1986. Retina 9:8–14
29. Ozdamar A, Aras C, Ozturk R, Akin E, Karacorlu M, Ercikan C (1999) In vitro antimicrobial activity of silicone oil against endophthalmitis-causing agents. Retina 19:122–126
30. Abu-Yaghi NE, Bakri SJ (2012) The use of antivascular endothelial growth factor agents in the perioperative period in diabetic vitrectomy. Middle East Afr J ophthalmol 19:83–87
31. Sun X, Xu X, Zhang X (2011) Counterfeit bevacizumab and endophthalmitis. N Engl J Med 365:378–379
32. Fintak DR, Shah GK, Blinder KJ et al (2008) Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 28:1395–1399
33. Mezad-Koursh D, Goldstein M, Heilwail G, Zayit-Soudry S, Loewenstein A, Barak A (2010) Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor. Retina 30:1051–1057
34. Diago T, McCannel CA, Bakri SJ, Pulido JS, Edwards AO, Pach JM (2009) Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 29:601–605
35. Pilli S, Kotsolis A, Spaide RF et al (2008) Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 145:879–882
36. Cavalcante LL, Cavalcante ML, Murray TG et al (2010) Intravitreal injection analysis at the Bascom palmer eye institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clin Ophthalmol 4:519–524
37. Cheng J-W, Wei R-L (2011) Ranibizumab for age-related macular degeneration. N Engl J Med 364:582
38. Lee SH, Woo SJ, Park KH et al (2010) Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab. Eye 24:226–232
39. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H et al (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246:81–87
40. Garcia-Aguirre G, Vanzinni-Zago V, Quiroz-Mercado H (2013) Growth of Scytalidium sp. In a counterfeit bevacizumab bottle. Indian J Ophthalmol 61:523–525
41. Results of the Endophthalmitis Vitrectomy Study (1995) A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol 113:1479–1496
42. Stewart MW (2013) Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol 7:1257–1267
43. Huang P, Niu W, Ni Z, Wang R, Sun X (2013) A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusion. PLoS One 8:e82454
44. Tan MH, McAllister IL, Gillies ME et al (2014) Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol 157:237–247